trending Market Intelligence /marketintelligence/en/news-insights/trending/ShUDPstqLrC31P97uUc8AQ2 content esgSubNav
In This List

Biohaven raises $143.7M in public offering of common shares

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Biohaven raises $143.7M in public offering of common shares

Biohaven Pharmaceutical Holding Co. Ltd. raised $143.7 million in a public offering of common shares after the underwriters fully exercised their options.

The company issued 3,859,060 common shares at $37.25 each for the offering, including the full exercise of underwriters' option to purchase additional shares. Expected gross proceeds had been set at $125 million.

Goldman Sachs & Co. LLC and Piper Jaffray & Co. acted as joint book-running managers for the offering, with Morgan Stanley and Cantor Fitzgerald & Co. as book runners. William Blair is the co-manager of the offering.

New Haven, Conn.-based Biohaven Pharmaceutical Holding is a clinical‑stage biopharmaceutical company that develops product candidates targeting migraine and neurological diseases, including rare disorders.